LP-922761

Cat. No.:	HY-120179			
CAS No.:	1454808-95-7			
Molecular Formula:	$C_{21}H_{26}N_6O_3$			
Molecular Weight:	410.47			
Target:	AAK1			
Pathway:	Neuronal Signaling			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

SOLVENT & SOLUBILITY

In Vitro

DMSO: 41.67 mg/mL (101.52 mM; ultrasonic and warming and heat to 80°C)

Preparing 1 mM Stock Solutions 5 mM	Solvent	1 mg	5 mg	10 mg
	1 mM	2.4362 mL	12.1812 mL	24.3623 mL
	0.4872 mL	2.4362 mL	4.8725 mL	
	10 mM	0.2436 mL	1.2181 mL	2.4362 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY				
DIOLOGICALACITY				
Description	LP-922761 is a potent, selective and orally active adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC ₅₀ s of 4.8 nM and 7.6 nM in enzyme and cell assays, respectively. LP-922761 also inhibits BMP-2-inducible protein kinase (BIKE) with an IC ₅₀ of 24 nM. LP-922761 exhibits no significant activity at cyclin G-associated kinase (GAK), opioid, adrenergic α2 or GABAa receptors ^[1] .			
IC ₅₀ & Target	IC50: 4.8 nM (Adapter protein-2 associated kinase 1 (AAK1) in enzyme assays); 7.6 nM (AAK1 in cell assays); 24 nM (BMP-2- inducible protein kinase (BIKE)) ^[1]			
In Vivo	In mouse, LP-922761 has a brain to plasma ratio of 0.007, indicating that LP-922761 is essentially restricted to the peripheral compartment ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

www.MedChemExpress.com

 $-NH_2$



[1]. Kostich W, et al. Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain. J Pharmacol Exp Ther. 2016 Sep;358(3):371-86.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA